Table 1 The details of individual study

Hong et al. (2010) [20]

tamsulosin plus dutasteride

tamsulosin

Oral

0 .2mg + 0 .5mg/0 .2mg

Men aged 45–75 years with moderate to severe symptomatic BPH, IPSS > 7, Qmax < 15 mL/s, PV ≥30 mL on TRUS, PSA < 10 ng/mL.

Previous treatment with a 5ARI or other hormonal drugs, endocrine disorder including diabetes mellitus, previous prostatic surgery within the past year.

Joo et al. (2012) [21]

tamsulosin plus dutasteride

tamsulosin

Oral

0 .2mg + 0 .5mg/0 .2mg

Age ≥ 40 years with diagnosis of BPH, IPSS ≥13, Qmax of 4–15 ml/s in a total voided volume ≥ 150 ml.

Patients had been treated previously for BPH, diagnosed with prostate cancer, bladder cancer or other progressive diseases that could cause LUTS; PVR > 200 ml.

Roehrborn et al. (2014) [22]

tamsulosin plus dutasteride

tamsulosin

Oral

0 .4mg + 0 .5mg/0 .4mg

Patients ≥50 years of age with diagnosis of BPH, IPSS ≥12, PV ≥30 mL, serum PSA ≥1.5 ng/mL, and Qmax > 5 mL/s and ≤ 15 mL/s with a minimum voided volume ≥ 125 mL.

Serum PSA > 10 ng/mL, history of prostate cancer and previous prostatic surgery, history of AUR within 3 months before entry, 5ARI use within 6 months before entry, or use of α-blocker within 2 weeks before entry.

Roehrborn et al. (2015) [23]

tamsulosin plus dutasteride

tamsulosin

Oral

0 .4mg + 0 .5mg/0 .4mg

Men aged ≥50 years with diagnosis of BPH and moderate LUTS, IPSS of 8–19, PV ≥30 cc by TRUS and serum PSA ≥1.5 ng/ml.

Serum PSA > 10.0 ng/ml, history or evidence of prostate cancer and any current or prior treatment related to BPH.

Choi et al. (2016) [24]

tamsulosin plus dutasteride

tamsulosin

Oral

0 .2mg + 0 .5mg/0 .2mg

Age ≥ 40, PV > 30 ml, IPSS ≥13, Qmax of 4–15 ml/s for a total voided volume of ≥150 ml, and no medical history relating to BPH during the previous 12 months.

Patients had allergies to α-blocker, conditions other than BPH that could induce LUTS, progressive diseases, or severe hepatic or renal dysfunction, PVR > 200 ml or serum PSA > 4 ng/ml.